Interleukin-1 receptor antagonist decreases severity of experimental acute pancreatitis
References (23)
- et al.
Anti-tumor necrosis factor antibody augments edema formation in caerulein-induced pancreatitis
J Surg Res
(1991) - et al.
Amelioration of the physiologic and biochemical changes of acute pancreatitis using an anti-TNF-α polyclonal antibody
Am J Surg
(1994) - et al.
Interleukin-1: biology, pathophysiology, and clinical prospects
Am J Med
(1990) - et al.
Role of pancreatic enzymes and their substrates in autodigestion of the pancreas
Gastroenterol
(1989) - et al.
Role of interleukin-6 in mediating the acute phase protein response and potential as an early means of severity assessment in acute pancreatitis
Pancreas
(1993) - et al.
Induction of tumor necrosis factor in severe acute pancreatitis and its subsequent reduction after hepatic passage
Surgery
(1994) - et al.
Rapid elevation of systemic cytokines during acute pancreatitis and their origination within the pancreas
Surg Forum
(1994) - et al.
Anticytokine strategies in the treatment of the systemic inflammatory response syndrome
JAMA
(1993) - et al.
An interleukin-1 receptor antagonist reduces mortality from endotoxin shock
Nature
(1990) - et al.
A specific receptor antagonist for interleukin-1 prevents E. coli induced shock in rabbits
FASEB J
(1991)
Interleukin-1 receptor antagonist blocks hypotension in a rabbit model of grampositive septic shock
Cytokine
(1991)
Cited by (235)
Fraxinellone inhibits inflammatory cell infiltration during acute pancreatitis by suppressing inflammasome activation
2019, International ImmunopharmacologyCitation Excerpt :IL-1β is known to be a major mediator of inflammation and injury responses in AP. Deficiency of IL-1R or injection of IL-1R antagonist attenuates the severity of AP [10,11] Constitutive overexpression of IL-1β in pancreatic acinar cells leads to pancreatic atrophy and fibrosis, suggesting that the expression of pancreatic IL-1β is sufficient to induce pancreatic damage [27]. Furthermore, IL-1β is a well-known final product from inflammasome activation [28].
Structure-activity relationship study of a series of novel oxazolidinone derivatives as IL-6 signaling blockers
2016, Bioorganic and Medicinal Chemistry Letters
Copyright © 1995 Published by Mosby, Inc.